Therapix Biosciences Ltd.’s (TRPX) Lock-Up Period Will End on September 18th
Therapix Biosciences’ (NASDAQ:TRPX) lock-up period will expire on Monday, September 18th. Therapix Biosciences had issued 2,000,000 shares in its initial public offering on March 22nd. The total size of the offering was $12,000,000 based on an initial share price of $6.00. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Separately, Ladenburg Thalmann Financial Services cut shares of Therapix Biosciences to a “buy” rating in a research note on Monday, June 5th.
COPYRIGHT VIOLATION NOTICE: “Therapix Biosciences Ltd.’s (TRPX) Lock-Up Period Will End on September 18th” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/11/therapix-biosciences-ltd-s-trpx-lock-up-period-will-end-on-september-18th.html.
Shares of Therapix Biosciences (NASDAQ:TRPX) opened at 5.70 on Monday. The stock’s 50 day moving average is $5.81 and its 200 day moving average is $6.82. The stock’s market capitalization is $19.71 million. Therapix Biosciences has a 52 week low of $5.21 and a 52 week high of $10.95.
Therapix Biosciences (NASDAQ:TRPX) last released its earnings results on Thursday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter. Analysts anticipate that Therapix Biosciences will post ($1.52) EPS for the current fiscal year.
Therapix Biosciences Company Profile
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.
Receive News & Ratings for Therapix Biosciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Therapix Biosciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.